BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10866395)

  • 1. SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors.
    Revesz L; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Zimmerlin AG
    Bioorg Med Chem Lett; 2000 Jun; 10(11):1261-4. PubMed ID: 10866395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.
    Laufer SA; Wagner GK; Kotschenreuther DA; Albrecht W
    J Med Chem; 2003 Jul; 46(15):3230-44. PubMed ID: 12852754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyridinylimidazole based p38 MAP kinase inhibitors.
    Jackson PF; Bullington JL
    Curr Top Med Chem; 2002 Sep; 2(9):1011-20. PubMed ID: 12171568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase.
    Fox T; Coll JT; Xie X; Ford PJ; Germann UA; Porter MD; Pazhanisamy S; Fleming MA; Galullo V; Su MS; Wilson KP
    Protein Sci; 1998 Nov; 7(11):2249-55. PubMed ID: 9827991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors.
    Revesz L; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Wolf R; Zimmerlin AG
    Bioorg Med Chem Lett; 2002 Aug; 12(16):2109-12. PubMed ID: 12127515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase.
    Wilson KP; McCaffrey PG; Hsiao K; Pazhanisamy S; Galullo V; Bemis GW; Fitzgibbon MJ; Caron PR; Murcko MA; Su MS
    Chem Biol; 1997 Jun; 4(6):423-31. PubMed ID: 9224565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis of inhibitor selectivity in MAP kinases.
    Wang Z; Canagarajah BJ; Boehm JC; Kassisà S; Cobb MH; Young PR; Abdel-Meguid S; Adams JL; Goldsmith EJ
    Structure; 1998 Sep; 6(9):1117-28. PubMed ID: 9753691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a new class of p38 kinase inhibitors.
    Dumas J; Sibley R; Riedl B; Monahan MK; Lee W; Lowinger TB; Redman AM; Johnson JS; Kingery-Wood J; Scott WJ; Smith RA; Bobko M; Schoenleber R; Ranges GE; Housley TJ; Bhargava A; Wilhelm SM; Shrikhande A
    Bioorg Med Chem Lett; 2000 Sep; 10(18):2047-50. PubMed ID: 10999467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity.
    Adams JL; Boehm JC; Gallagher TF; Kassis S; Webb EF; Hall R; Sorenson M; Garigipati R; Griswold DE; Lee JC
    Bioorg Med Chem Lett; 2001 Nov; 11(21):2867-70. PubMed ID: 11597418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase.
    Gallagher TF; Seibel GL; Kassis S; Laydon JT; Blumenthal MJ; Lee JC; Lee D; Boehm JC; Fier-Thompson SM; Abt JW; Soreson ME; Smietana JM; Hall RF; Garigipati RS; Bender PE; Erhard KF; Krog AJ; Hofmann GA; Sheldrake PL; McDonnell PC; Kumar S; Young PR; Adams JL
    Bioorg Med Chem; 1997 Jan; 5(1):49-64. PubMed ID: 9043657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
    Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
    J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The non-diaryl heterocycle classes of p38 MAP kinase inhibitors.
    Cirillo PF; Pargellis C; Regan J
    Curr Top Med Chem; 2002 Sep; 2(9):1021-35. PubMed ID: 12171569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated levels of cyclooxygenase-2 in antigen-stimulated mast cells is associated with minimal activation of p38 mitogen-activated protein kinase.
    Hundley TR; Prasad AR; Beaven MA
    J Immunol; 2001 Aug; 167(3):1629-36. PubMed ID: 11466386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benzimidazolone p38 inhibitors.
    Dombroski MA; Letavic MA; McClure KF; Barberia JT; Carty TJ; Cortina SR; Csiki C; Dipesa AJ; Elliott NC; Gabel CA; Jordan CK; Labasi JM; Martin WH; Peese KM; Stock IA; Svensson L; Sweeney FJ; Yu CH
    Bioorg Med Chem Lett; 2004 Feb; 14(4):919-23. PubMed ID: 15012994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imidazopyrimidines, potent inhibitors of p38 MAP kinase.
    Rupert KC; Henry JR; Dodd JH; Wadsworth SA; Cavender DE; Olini GC; Fahmy B; Siekierka JJ
    Bioorg Med Chem Lett; 2003 Feb; 13(3):347-50. PubMed ID: 12565927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of p90RSK and cAMP response element binding protein in stimulated neutrophils: novel effects of the pyridinyl imidazole SB 203580 on activation of the extracellular signal-regulated kinase cascade.
    Lian JP; Huang R; Robinson D; Badwey JA
    J Immunol; 1999 Oct; 163(8):4527-36. PubMed ID: 10510396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibitor of p38 mitogen-activated protein kinase inhibits lipopolysaccharide-induced interleukin-8 expression in human pulmonary vascular endothelial cells.
    Hashimoto S; Gon Y; Matsumoto K; Maruoka S; Takeshita I; Hayashi S; Asai Y; Jibiki I; Machino T; Horie T
    J Pharmacol Exp Ther; 2000 May; 293(2):370-5. PubMed ID: 10773004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase.
    Kumar S; Jiang MS; Adams JL; Lee JC
    Biochem Biophys Res Commun; 1999 Oct; 263(3):825-31. PubMed ID: 10512765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion.
    Simon C; Goepfert H; Boyd D
    Cancer Res; 1998 Mar; 58(6):1135-9. PubMed ID: 9515796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.
    Laping NJ; Grygielko E; Mathur A; Butter S; Bomberger J; Tweed C; Martin W; Fornwald J; Lehr R; Harling J; Gaster L; Callahan JF; Olson BA
    Mol Pharmacol; 2002 Jul; 62(1):58-64. PubMed ID: 12065755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.